Parenteral systemic antifungal drugs and their clinical drug informations
Yükleniyor...
Dosyalar
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Abstract: Invasive fungal infections are an important cause of morbidity and mortality, especially in with patients’ immune-compromised conditions such as AIDS, cancer, diabetes and burn patients, neonates, organ transplant patients. Therefore, treatment of fungal infections is still a major problem. The drugs used to treat these infections are very limited due to toxicity or inappropriate pharmacokinetic properties. Nowadays, there are three molecules class used in the clinical for these infections: polyenes, azoles and echinocandins. Amphotericin B and lipid formulations have been used for a long time in the treatment of these infections. The development of new triazole derivatives has provided different treatment options (fluconazole, voriconazole and posaconazole). In addition, three echinocandin derivatives (caspofungin, micafungin, and anidulafungin) have been approved for use in medication. The broad-spectrum triazoles and echinocandin derivative drugs have offer more effective and less toxic alternatives to antifungal therapy. This review provides a brief of the pharmacologic principles and clinical usage involved in treatment of systemic fungal infections.
Açıklama
Anahtar Kelimeler
Kaynak
Medicine Science
WoS Q Değeri
Scopus Q Değeri
Cilt
8
Sayı
1
Künye
BOZBEY İ,GÜN Z. Ü,KARAKURT A (2019). Parenteral systemic antifungal drugs and their clinical drug informations. Medicine Science, 8(1), 250 - 254. Doi: 10.5455/medscience.2018.07.8915
